Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases
Evaluation of the Abbott Architect, Roche Elecsys and Virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases
复制标题
对社区管理的 COVID-19 病例中 Abbott Architect、Roche Elecsys 和 Virtus S1 SARS-CoV-2 抗体测试的评估
DOI：
10.1101/2020.10.27.20220509
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Johnston S
中科院分区：
文献类型：
--
作者：
Johnston S
背景抗体检测可以帮助确定对SARS-CoV-2的保护性免疫力以及这种免疫力持续多长时间。许多抗体检测是在住院而不是社区的COVID-19病例中进行评估的。Virtus Respiratory Research Ltd（Virtus）开发了自己的定量IgM和IgG SARS CoV-2抗体检测。我们报告了它的验证和性能特点，并将其性能与社区COVID cases.MethodsWe开发了一种定量抗体检测SARS-CoV-2 S1刺突蛋白的IgM和IgG进行了比较（Virtus检测），并在来自106例社区管理和1例住院COVID-19病例的107份“真阳性”血清和208份“真阴性”血清中验证了该检测血清样本我们根据中和抗体试验验证了Virtus试验。我们在107个真阳性样本中确定了Abbott检测的灵敏度，在75个真阳性样本的子集中确定了Roche检测的灵敏度。结果Virtus定量检测在107个COVID-19社区病例中的93个（87%）中呈阳性，IgM和IgG水平与中和抗体滴度密切相关（对于IgM，r=0.75，对于IgG，r=0.71，对于两种抗体，P<0.0001）。Virtus检测的特异性为98.6%，为低水平抗体阳性，99.5%为中度阳性和100%为高或非常高的阳性。Abbott测试的灵敏度为68%。结论Abbott和Roche两种试剂盒对该社区人群的敏感性分别为68%和69%，而Virtus两种试剂盒对该社区人群的敏感性分别为87%和91%。与病毒中和的强正相关性表明，Virtus定量抗体检测阳性可能预示着对COVID-19复发的保护作用。基金Virtus检测和所有抗体检测的样本检测的开发由Virtus呼吸研究有限公司资助。提供208个“真阴性”样本中的111个的研究研究得到了MRC资助号MR/M025330/1和G1100238以及国立卫生研究院（NIHR）帝国生物医学研究中心（BRC），SLJ是NIHR名誉高级研究员，部分由欧洲研究理事会高级资助788575和哮喘英国临床主席（资助CH 11 SJ）资助。所表达的观点是作者的观点，不一定是国家人权研究所或卫生和社会福利部的观点。
BackgroundAntibody testing can help define how protective immunity to SARS-CoV-2 is and how long this immunity lasts. Many antibody tests have been evaluated in hospitalised rather than community based COVID-19 cases. Virtus Respiratory Research Ltd (Virtus) has developed its own quantitative IgM and IgG SARS CoV-2 antibody assay. We report its validation and performance characteristics and compare its performance with the Abbott Architect and Roche Elecsys assays in community COVID cases.MethodsWe developed a quantitative antibody test to detect IgM and IgG to the SARS-CoV-2 S1 spike protein (the Virtus test) and validated this test in 107 “true positive” sera from 106 community-managed and 1 hospitalised COVID-19 cases and 208 “true negative” serum samples. We validated the Virtus test against a neutralising antibody test. We determined sensitivities of the Abbott test in the 107 true positive samples and the Roche test in a subset of 75 true positive samples.ResultsThe Virtus quantitative test was positive in 93 of 107 (87%) community cases of COVID-19 and both IgM and IgG levels correlated strongly with neutralising antibody titres (r=0.75 for IgM, r=0.71 for IgG,P<0.0001 for both antibodies). The specificity of the Virtus test was 98.6% for low level antibody positives, 99.5% for moderate positives and 100% for high or very high positives. The Abbott test had a sensitivity of 68%. In the 75 sample subset, the Virtus test was positive in 91%, the Roche test in 69%.ConclusionsThe Abbott and Roche tests had sensitives of 68% and 69% respectively in this community set of COVID-19 sera, while the Virtus test had sensitivities of 87% and 91% in the same sample sets. The strong positive correlation with virus neutralization suggests a positive Virtus quantitative antibody test is likely predictive of protective against recurrent COVID-19.FundingThe development of the Virtus test and sample testing with all antibody tests was funded by Virtus Respiratory Research Ltd. The research studies providing 111 of the 208 of the “true negative” samples was supported by MRC Grant numbers MR/M025330/1 and G1100238 and by the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC), SLJ is a NIHR Emeritus Senior Investigator and is funded in part by European Research Council Advanced Grant 788575 and the Asthma UK Clinical Chair (grant CH11SJ). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
SARS-CoV-2 T 细胞表位定义异源和 COVID-19 诱导的 T 细胞识别
DOI：
--
发表时间：
2020
期刊：
影响因子：
--
作者：
A. Nelde;Tatjana Bilich;J. Heitmann;Y. Maringer;H. Salih;Malte Roerden;Maren Lübke;Jens Bauer;J. Rieth;Marcel Wacker;Andreas Peter;Sebastian Hörber;B. Traenkle;P. Kaiser;U. Rothbauer;M. Becker;D. Junker;G. Krause;M. Strengert;N. Schneiderhan;M. Templin;T. Joos;D. Kowalewski;Vlatka Stos;M. Fehr;M. Graf;Lena;David Rachfalski;B. Preuß;Ilona Hagelstein;Melanie Märklin;T. Bakchoul;C. Gouttefangeas;O. Kohlbacher;R. Klein;S. Stevanović;H. Rammensee;J. Walz
通讯作者：
J. Walz
影响因子：
4.2
作者：
CALLOW, KA;PARRY, HF;TYRRELL, DAJ
通讯作者：
TYRRELL, DAJ
影响因子：
64.5
作者：
Grifoni, Alba;Weiskopf, Daniela;Sette, Alessandro
通讯作者：
Sette, Alessandro